The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), for use in cancer patients at risk of infection due to chemotherapy. Filkri is indicated for patients receiving ...
The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...
Add Yahoo as a preferred source to see more of our stories on Google. Kelly said she suffered from bone marrow pain from filgrastim injections (Collect/PA Real Life) A 25-year-old woman says a GP ...
GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of Cincinnati's best-funded ...
A Boxed Warning explaining the risk of medication errors involving inadvertent neuraxial administration will be added to the labeling. The Food and Drug Administration (FDA) has issued an updated ...
One administration official is leading a government-funded cultural institution in Washington as he conducts diplomatic talks with foreign countries. Another is in charge of two agencies, each with ...
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results